Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 8/2021

01-08-2021 | Computed Tomography | Original Article

Texture analysis of [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography for predicting the treatment response of postoperative recurrent or metastatic oral squamous cell carcinoma treated with cetuximab

Authors: Mai Kim, Wenchao Gu, Takahito Nakajima, Tetsuya Higuchi, Masaru Ogawa, Takahiro Shimizu, Takahiro Yamaguchi, Ayako Takahashi, Yoshito Tsushima, Satoshi Yokoo

Published in: Annals of Nuclear Medicine | Issue 8/2021

Login to get access

Abstract

Objective

To assess the value of the texture analysis of fluorine-18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) in predicting the treatment response of postoperative recurrent or metastatic oral squamous cell carcinoma (POR/M-OSCC) treated with cetuximab.

Methods

A total of 14 patients undergoing 18F-FDG-PET/CT with POR/M-OSCC were divided into the responder and non-responder groups according to cetuximab response by Response Evaluation Criteria in Solid Tumors (RECIST). The regions of interest (ROI) were set at the POR/M-OSCC lesions with the highest uptake of 18F-FDG, and the volumetric and texture features were analyzed. The features with correlation coefficient of 0.6 or more were further evaluated using the logistic regression analysis to create a model.

Results

The SHAPEVolume(vx), SHAPEVolume(mL), metabolic tumor volume (MTV), and gray-level run-length matrix run-length nonuniformity (GLRLMRLNU) were significantly different between the responder (n = 6) and non-responder (n = 8) groups (p = 0.044, 0.042, 0.047, and 0.012, respectively). The model’s area under the curve (AUC) was found to be 0.83, 0.83, 0.79, and 0.92, respectively. The heatmap with PET feature dendrogram showed four distinct clusters including them in patient’s responder and non-responder groups.

Conclusions

Higher MTV, GLRLMRLNU, SHAPEVolume(vx), and SHAPEVolume(mL) in 18F-FDG-PET images may have the prediction values for treatment response with POR/M-OSCC treated with cetuximab.
Literature
1.
Adelstein D, Ml G, Pfister DG, Spencer S, Adkins D, Brizel DM, et al. Nccn guidelines insights: head and neck cancers, Version 2.2017. J Natl Compr Canc Netw. 2017;15:761–70.CrossRef
2.
Wa M, Dj A. Targeting egfr in colorectal cancer. N Engl J Med. 2008;359:1834–6.CrossRef
3.
Lk L, Xy J, Xx Z, Dm W, Xl S, Hb J. Upregulation of vimentin and aberrant expression of e-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol. 2010;23:213–24.CrossRef
4.
Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015–24.CrossRef
5.
Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, et al. High incidence of P53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene. 1995;10:1217–27.PubMed
6.
Avissar M, Mcclean MD, Kelsey KT, Marsit CJ. Microrna expression in head and neck cancer associates with alcohol consumption and survival. Carcinogenesis. 2009;30:2059–63.CrossRef
7.
Hoffmann TK, Schuler PJ, Laban S, Grässlin R, Beer M, Beer AJ, et al. Response evaluation in head and neck oncology: definition and prediction. Orl J Otorhinolaryngol Relat Spec. 2017;79:14–23.CrossRef
8.
Parks SK, Chiche J, Pouysségur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer. 2013;13:611–23.CrossRef
9.
Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.PubMed
10.
Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying tumour heterogeneity in 18f-fdg pet/ct imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40:133–40.CrossRef
11.
Na KJ, Choi H. Tumor metabolic features identified by 18f-fdg pet correlate with gene networks of immune cell microenvironment in head and neck cancer. J Nucl Med. 2018;59:31–7.CrossRef
12.
Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, et al. Lifex: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786–9.CrossRef
13.
Kim M, Achmad A, Higuchi T, et al. Effects of intratumoral inflammatory process on 18f-fdg uptake: pathologic and comparative study with 18f-fluoro-α-methyltyrosine Pet/Ct in oral squamous cell carcinoma. J Nucl Med. 2015;56:16–21.CrossRef
14.
Kim M, Higuchi T, Nakajima T, Andriana P, Hirasawa H, Tokue A, et al. F-Fdg and 18f-famt pet-derived metabolic parameters predict outcome of oral squamous cell carcinoma. Oral Radiol. 2019;35:308–14.CrossRef
15.
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.CrossRef
16.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.CrossRef
17.
Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ. Phase Ii study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23:1016–22.CrossRef
18.
Péron J, Ceruse P, Lavergne E, Buiret G, Pham BN, Chabaud S, et al. Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Anticancer Drugs. 2012;23:996–1001.CrossRef
19.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised recist guideline (Version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef
20.
Abd El-Hafez YG, Moustafa HM, Khalil HF, Liao CT, Yen TC. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma. Oral Oncol. 2013;49:261–8.CrossRef
21.
Mk C, Hs J, Yi S, Yk So, Gy P, Jy C, et al. Metabolic tumor volumes by [18f]-fluorodeoxyglucose Pet/Ct correlate with occult metastasis in oral squamous cell carcinoma of the tongue. Ann Surg Oncol. 2009;16:3111–7.CrossRef
22.
Maffione AM, Ferretti A, Grassetto G, et al. Fifteen different 18f-Fdg Pet/Ct qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging. 2013;40:853–64.CrossRef
23.
Hj Im, Yk K, Yi K, Jj L, Ww L, Se K. Usefulness Of combined metabolic-volumetric indices of (18)F-Fdg Pet/Ct for the early prediction of neoadjuvant chemotherapy outcomes in breast cancer. Nucl Med Mol Imaging. 2013;47:36–43.CrossRef
24.
Pinho DF, King B, Xi Y, Albuquerque K, Lea J, Subramaniam RM. Value of intratumoral metabolic heterogeneity and quantitative. Ajr Am J Roentgenol. 2020;214:908–16.CrossRef
25.
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.CrossRef
26.
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.CrossRef
27.
Yanamoto S, Umeda M, Kioi M, Kirita T, Yamashita T, Hiratsuka H, et al. Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma. Cancer Chemother Pharmacol. 2018;81:549–54.CrossRef
28.
Tsujikawa T, Rahman T, Yamamoto M, Yamada S, Tsuyoshi H, Kiyono Y, et al. F-Fdg pet radiomics approaches: comparing and clustering features in cervical cancer. Ann Nucl Med. 2017;31:678–85.CrossRef
29.
Sf P, Ka G, Mm G, Cj S, Mm L, Sc M, et al. Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase Ib study. J Clin Oncol. 2020;38:2427–37.CrossRef
Metadata
Title
Texture analysis of [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography for predicting the treatment response of postoperative recurrent or metastatic oral squamous cell carcinoma treated with cetuximab
Authors
Mai Kim
Wenchao Gu
Takahito Nakajima
Tetsuya Higuchi
Masaru Ogawa
Takahiro Shimizu
Takahiro Yamaguchi
Ayako Takahashi
Yoshito Tsushima
Satoshi Yokoo
Publication date
01-08-2021
Publisher
Springer Singapore
Published in
Annals of Nuclear Medicine / Issue 8/2021
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-021-01623-6

Other articles of this Issue 8/2021

Annals of Nuclear Medicine 8/2021 Go to the issue

Original Article

Detection of Alzheimer’s disease using ECD SPECT images by transfer learning from FDG PET

Review Article

177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements

Original Article

Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT

Original Article

Left-ventricular dyssynchrony in viable myocardium by myocardial perfusion SPECT is predictive of mechanical response to CRT

Original Article

Quality and utility of [123I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator

Original Article

Automatic quantification package (Hone Graph) for phantom-based image quality assessment in bone SPECT: computerized automatic classification of detectability